AXSM - Axsome Therapeutics - Stock Price & Dividends

Axsome Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative treatments for central nervous system (CNS) disorders in the United States. Their current commercial product portfolio includes Auvelity, a novel medication that targets major depressive disorder by modulating the brain's N-methyl-D-aspartate receptor, and Sunosi, a treatment for excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

The company has a robust pipeline of investigational medicines in various stages of clinical development. AXS-05, a promising candidate, is currently in Phase III clinical trials for the treatment of Alzheimer's disease agitation and has also shown potential in smoking cessation. AXS-07, another investigational medicine, has completed Phase III trials for the acute treatment of migraine, offering a potential new solution for this debilitating condition.

Axsome Therapeutics is also advancing AXS-12, which is in Phase III trials for the treatment of narcolepsy, and AXS-14, a selective norepinephrine reuptake inhibitor that has completed Phase III trials for the treatment of fibromyalgia and other conditions. Additionally, solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder and is being evaluated in Phase 2 trials for major depressive disorder, binge eating disorder, and shift work disorder.

The company has a research collaboration agreement with Duke University to evaluate AXS-05 in smoking cessation, further expanding its research capabilities. Founded in 2012, Axsome Therapeutics Inc is headquartered in New York, New York, and is committed to developing innovative treatments that address significant unmet medical needs in CNS disorders.